Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease.
D000368:Aged; D000588:Amines / Q000032:analysis*; D001923:Brain Chemistry / Q000187:drug effects*; D002525:Cerebellar Cortex / Q000032:analysis; D002540:Cerebral Cortex / Q000032:analysis; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000032:analysis; D005116:Extrapyramidal Tracts / Q000032:analysis; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000032:analysis; D007031:Hypothalamus / Q000032:analysis; D008297:Male; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy*; D010648:Phenylacetates / Q000032:analysis; D012701:Serotonin / Q000032:analysis; D013788:Thalamus / Q000032:analysis
D000588:Amines; D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine